Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience

PURPOSE: We sought to develop placental growth factor as a predictive pharmacodynamic biomarker for motesanib efficacy as first-line therapy in patients with advanced nonsquamous non–small-cell lung cancer. EXPERIMENTAL DESIGN: Placental growth factor was evaluated at baseline and study week 4 (afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Bass, Michael B., Yao, Bin, Hei, Yong-Jiang, Ye, Yining, Davis, Gerard J., Davis, Michael T., Kaesdorf, Barbara A., Chan, Sabrina S., Patterson, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196848/
https://www.ncbi.nlm.nih.gov/pubmed/25314641
http://dx.doi.org/10.1371/journal.pone.0108048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196848/
https://www.ncbi.nlm.nih.gov/pubmed/25314641
http://dx.doi.org/10.1371/journal.pone.0108048

Ejemplares similares